Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria.
Department of Anesthesiology and Intensive Care, Danube Hospital, Langobardenstraße 122, Vienna 1220, Austria.
Eur Heart J. 2021 Jun 14;42(23):2299-2307. doi: 10.1093/eurheartj/ehab171.
An interrelation between cancer and thrombosis is known, but population-based studies on the risk of both arterial thromboembolism (ATE) and venous thromboembolism (VTE) have not been performed.
International Classification of Disease 10th Revision (ICD-10) diagnosis codes of all publicly insured persons in Austria (0-90 years) were extracted from the Austrian Association of Social Security Providers dataset covering the years 2006-07 (n = 8 306 244). Patients with a history of cancer or active cancer were defined as having at least one ICD-10 'C' diagnosis code, and patients with ATE and/or VTE as having at least one of I21/I24 (myocardial infarction), I63/I64 (stroke), I74 (arterial embolism), and I26/I80/I82 (venous thromboembolism) diagnosis code. Among 158 675 people with cancer, 8559 (5.4%) had an ATE diagnosis code and 7244 (4.6%) a VTE diagnosis code. In contrast, among 8 147 569 people without cancer, 69 381 (0.9%) had an ATE diagnosis code and 29 307 (0.4%) a VTE diagnosis code. This corresponds to age-stratified random-effects relative risks (RR) of 6.88 [95% confidence interval (CI) 4.81-9.84] for ATE and 14.91 (95% CI 8.90-24.95) for VTE. ATE proportion was highest in patients with urinary tract malignancies (RR: 7.16 [6.74-7.61]) and lowest in patients with endocrine cancer (RR: 2.49 [2.00-3.10]). The corresponding VTE proportion was highest in cancer of the mesothelium/soft tissue (RR: 19.35 [17.44-21.47]) and lowest in oropharyngeal cancer (RR: 6.62 [5.61-7.81]).
The RR of both ATE and VTE are significantly higher in persons with cancer. Our population-level meta-data indicate a strong association between cancer, ATE and VTE, and support the concept of shared risk factors and pathobiology between these diseases.Relative risk of ATE and VTE in persons with a cancer diagnosis code versus persons without a cancer diagnosis code.
已知癌症与血栓之间存在关联,但尚未开展基于人群的动脉血栓栓塞(ATE)和静脉血栓栓塞(VTE)风险研究。
从涵盖 2006-07 年的奥地利社会保障提供者数据集(奥地利协会)中提取所有公共保险人群(0-90 岁)的国际疾病分类第 10 版(ICD-10)诊断代码。患有癌症或活动性癌症的患者被定义为至少有一个 ICD-10“C”诊断代码,患有 ATE 和/或 VTE 的患者至少有一个 I21/I24(心肌梗死)、I63/I64(中风)、I74(动脉栓塞)和 I26/I80/I82(静脉血栓栓塞)诊断代码。在 158675 名癌症患者中,8559 名(5.4%)有 ATE 诊断代码,7244 名(4.6%)有 VTE 诊断代码。相比之下,在 8147569 名无癌症的患者中,69381 名(0.9%)有 ATE 诊断代码,29307 名(0.4%)有 VTE 诊断代码。这对应于年龄分层随机效应的相对风险(RR)分别为 6.88(95%置信区间[CI]为 4.81-9.84)的 ATE 和 14.91(95%CI 为 8.90-24.95)的 VTE。在患有泌尿道恶性肿瘤的患者中 ATE 比例最高(RR:7.16[6.74-7.61]),在患有内分泌癌的患者中比例最低(RR:2.49[2.00-3.10])。相应的 VTE 比例在间皮/软组织癌症(RR:19.35[17.44-21.47])中最高,在口咽癌中最低(RR:6.62[5.61-7.81])。
癌症患者的 ATE 和 VTE 的 RR 明显更高。我们的人群水平荟萃数据分析表明癌症、ATE 和 VTE 之间存在很强的关联,并支持这些疾病之间存在共同风险因素和病理生物学的概念。
患有癌症诊断代码的人与无癌症诊断代码的人相比,ATE 和 VTE 的相对风险。